Related references
Note: Only part of the references are listed.Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
Rebecca Goldstein et al.
Cancer Management and Research (2016)
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009
K. I. Kaitin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
DEGARELIX ACETATE FOR THE TREATMENT OF PROSTATE CANCER
Laurence Klotz
DRUGS OF TODAY (2009)
Treanda approved for chronic lymphocytic leukemia
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
The risk we bear: The effects of review speed and industry user fees on new drug safety
Mary K. Olson
JOURNAL OF HEALTH ECONOMICS (2008)
Drug-review deadlines and safety problems
Daniel Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act
Henry Grabowski et al.
JOURNAL OF LAW & ECONOMICS (2008)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Economics of new oncology drug development
Joseph A. DiMasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reimbursement for cancer treatment: Coverage of off-label drug indications
JOURNAL OF CLINICAL ONCOLOGY (2006)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates
ER Berndt et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
C Sessa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical research by community oncologists
GI Cohen
CA-A CANCER JOURNAL FOR CLINICIANS (2003)
STI571 (imatinib mesylate): the tale of a targeted therapy
P Thambi et al.
ANTI-CANCER DRUGS (2002)
Share Paper
